BDBM235033 US9556168, 10C
SMILES: OC(=O)c1ccc(-c2nn(Cc3c(Cl)cccc3C(F)(F)F)c3cc(cc(F)c23)C(=O)N2CCC2)c(F)c1
InChI Key: InChIKey=HYEIELMRFQPSKL-UHFFFAOYSA-N
Data: 1 IC50
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nuclear receptor ROR-gamma (RORC) (Homo sapiens (Human)) | BDBM235033 (US9556168, 10C) | PDB UniProtKB/SwissProt UniProtKB/TrEMBL antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 3 | n/a | n/a | n/a | n/a | 7.0 | n/a |
Merck Sharp & Dohme Corp. US Patent | Assay Description The compounds of the invention inhibit RORgammaT activity. Activation of RORgammaT activity can be measured using, e.g., biochemical TR-FRET assay. I... | US Patent US9556168 (2017) BindingDB Entry DOI: 10.7270/Q2D220MV | |||||||||||
More data for this Ligand-Target Pair |